Bremelanotide

What it's for

Bremelanotide is a lab-made ring-shaped peptide that turns on melanocortin receptors (lock-and-key landing spots on cells). In the U.S. it is the active ingredient in Vyleesi, a prescription medicine for a specific sexual-desire problem. It treats acquired, generalized low sexual desire that causes distress (HSDD (bothersome low sexual desire)) in premenopausal women.

What it does for the body

It treats acquired, generalized low sexual desire that causes distress (HSDD (bothersome low sexual desire)) in premenopausal women. It is not approved as a general "libido booster" for everyone, and it is not approved for men.

What it targets

It stimulates melanocortin receptors (landing spots on cells) — especially pathways involving MC4R (a brain melanocortin pathway tied to appetite and energy) — that influence brain circuits tied to sexual arousal. Effects are mainly brain-based, not the same as common erectile medicines that widen blood vessels in the genitals. It is given as a small under-the-skin shot from a ready-to-use pen when needed, under a clinician's labeled plan. Picture lock-and-key: the medicine is a key that flips desire-related brain pathways.

Research context

Bottom line for readers: Bremelanotide has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.

Studied for (literature interest)

• Brain research interest (educational tag)

Cautions (educational)

• Educational only — not medical advice.
• DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.

Citations / starters

• FDA search: Bremelanotide — FDA.gov search
• ClinicalTrials.gov search: Bremelanotide — U.S. clinical trials registry
• Drugs@FDA search: Bremelanotide — FDA drug database (if approved)
• PubMed search: Bremelanotide — NCBI PubMed
• PubMed Central search: Bremelanotide — NCBI PMC

Reference

$599